Limitations, agreements, and source contact

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer · Source last updated 2020-09-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

point Of Contact

email

asiefker@mdanderson.org

organization

UT MD Anderson Cancer Center

phone

(713) 792-2830

title

Dr. Arlene O. Siefker-Radtke,Professor, Genitourinary Medical Oncology

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice